… of pancreatic cancer is a consequence of disappointing treatment efficacy [2], [3]. Standard
therapy for patients with metastatic pancreatic cancer is … for operable pancreatic cancer, with a …

… suitable tool for pancreatic cancer preclinical studies. Our data also suggest that aberrant
proliferation events take place early in pancreatic carcinogenesis, before tumour appearance. …

… Preclinical evaluations of combining a PI3K/AKT inhibitor and a MEK inhibitor in pancreatic
cancer … Our study supports a similar preclinical study in pancreatic cancer which showed that …

… The use of orthotopic animal models of pancreatic cancer in the preclinical evaluation of … ,
orthotopic mouse model of pancreatic cancer that uses the MIA-PaCa-2 pancreatic cancer cell …

… recapitulate the functional heterogeneity of human pancreatic tumors harboring distinct cells
… of the KPC mouse model. We isolated pancreatic cancer cells from multiple independent …

… models of pancreatic cancer. We selected pancreatic cancer as our disease model in light of
… for most individuals with advanced pancreatic cancer, current chemotherapeutic modalities (…

… cancer [10], but it could also influence pancreatic cancer tumorigenesis [11] because it is
often overexpressed in pancreatic cancer … , particularly in pancreatic cancer where it regulates …

… the popular models. Ultimately we will argue that there is no perfect model and that the best
approach to understanding clinical performance is the use of multiple preclinical models with …

… Ductal Epithelial (HPDE) and Human Pancreatic Nestin-expressing (HPNE) cells. While the
reach of these preclinical models in furthering our knowledge of PDAC biology is extensive 1…

… This study aimed to determine the therapeutic role of inhibiting mTOR in preclinical models
of pancreatic cancer and in patients with this disease. The mTOR inhibitor, temsirolimus, …